MX2021011676A - Polimorfos de sepiapterina y sales de los mismos. - Google Patents
Polimorfos de sepiapterina y sales de los mismos.Info
- Publication number
- MX2021011676A MX2021011676A MX2021011676A MX2021011676A MX2021011676A MX 2021011676 A MX2021011676 A MX 2021011676A MX 2021011676 A MX2021011676 A MX 2021011676A MX 2021011676 A MX2021011676 A MX 2021011676A MX 2021011676 A MX2021011676 A MX 2021011676A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphs
- sepiapterin
- salts
- disclosed
- crystalline
- Prior art date
Links
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 title abstract 4
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 title abstract 4
- 229940126478 sepiapterin Drugs 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 2
- 201000011252 Phenylketonuria Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen formas cristalinas de base libre de sepiapterina seleccionadas a partir de polimorfos A, B, C, D, E, F y G, y combinaciones de los mismos, así como polimorfos cristalinos de sales de sepiapterina. También se describen composiciones farmacéuticas que contienen uno o más de tales polimorfos y métodos para preparar dichos polimorfos. La sepiapterina es útil en el tratamiento contra una diversidad de enfermedades asociadas con bajos niveles celulares de BH4, por ejemplo, fenilcetonuria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427686P | 2016-11-29 | 2016-11-29 | |
| US201762546390P | 2017-08-16 | 2017-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011676A true MX2021011676A (es) | 2021-10-22 |
Family
ID=62241930
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006206A MX2019006206A (es) | 2016-11-29 | 2017-11-28 | Polimorfos de sepiapterina y sales de los mismos. |
| MX2021011676A MX2021011676A (es) | 2016-11-29 | 2019-05-28 | Polimorfos de sepiapterina y sales de los mismos. |
| MX2021011683A MX2021011683A (es) | 2016-11-29 | 2019-05-28 | Polimorfos de sepiapterina y sales de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006206A MX2019006206A (es) | 2016-11-29 | 2017-11-28 | Polimorfos de sepiapterina y sales de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011683A MX2021011683A (es) | 2016-11-29 | 2019-05-28 | Polimorfos de sepiapterina y sales de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11072614B2 (es) |
| EP (1) | EP3548497A4 (es) |
| JP (2) | JP7148533B2 (es) |
| KR (2) | KR20230117467A (es) |
| CN (2) | CN110248948B (es) |
| AU (3) | AU2017366879C1 (es) |
| BR (2) | BR112019010222A8 (es) |
| CA (1) | CA3043502A1 (es) |
| CO (1) | CO2019006018A2 (es) |
| IL (2) | IL301470A (es) |
| MA (1) | MA46973A (es) |
| MX (3) | MX2019006206A (es) |
| WO (1) | WO2018102315A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5066756B2 (ja) | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| EP3548487A4 (en) | 2016-11-29 | 2020-04-29 | Censa Pharmaceuticals Inc. | POLYMORPHE SHAPE OF SEPIAPTERIN |
| BR112019010222A8 (pt) | 2016-11-29 | 2022-11-22 | Censa Pharmaceuticals Inc | Polimorfos de sepiapterina e sais dos mesmos |
| WO2019046849A1 (en) * | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| AU2019277372A1 (en) * | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| CN112703002A (zh) | 2018-05-30 | 2021-04-23 | Ptc医疗Mp公司 | 增加墨蝶呤血浆暴露的方法 |
| US20210161901A1 (en) * | 2018-05-30 | 2021-06-03 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| WO2021026247A1 (en) | 2019-08-05 | 2021-02-11 | Ptc Therapeutics Mp, Inc. | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| JP2022549834A (ja) * | 2019-09-25 | 2022-11-29 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 高フェニルアラニン血症の治療方法 |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| EP4291196A1 (en) | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
| AU2022221345A1 (en) | 2021-02-09 | 2023-09-07 | Ptc Therapeutics Mp, Inc. | Methods for treating glioblastomas with sepiapterin |
| IL311716A (en) | 2021-09-29 | 2024-05-01 | Ptc Therapeutics Inc | Pharmaceutical compositions of Spiafetrin |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| CA2228970A1 (en) | 1995-08-18 | 1997-02-27 | Donald W. Landry | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| WO2005065018A2 (en) | 2003-11-17 | 2005-07-21 | Merck Eprova Ag | Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride |
| BRPI0517088A (pt) | 2004-11-17 | 2008-09-30 | Biomarin Pharm Inc | formulação de comprimido estável |
| AU2005313940A1 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| EP1877370B1 (en) | 2005-04-28 | 2009-02-25 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20170037676A (ko) | 2007-04-11 | 2017-04-04 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| CN102026994B (zh) | 2008-03-10 | 2014-05-07 | 武田药品工业株式会社 | 苯并咪唑化合物的晶体 |
| PL2309983T3 (pl) | 2008-08-12 | 2019-09-30 | Orpha Swiss Gmbh | Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę |
| KR20110103968A (ko) | 2008-12-23 | 2011-09-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 유기 화합물의 염 형태 |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| JP5066756B2 (ja) | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| WO2012117362A1 (en) | 2011-03-01 | 2012-09-07 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| EP2848619B1 (en) * | 2012-05-07 | 2018-07-11 | Shiratori Pharmaceutical Co., Ltd. | Method for producing sepiapterin and tetrahydrolactoylpterin |
| JP2019527242A (ja) | 2016-07-29 | 2019-09-26 | ディファーマ エッセ．ア． | サプロプテリンジヒドロクロリドを含む医薬組成物キット |
| BR112019010222A8 (pt) | 2016-11-29 | 2022-11-22 | Censa Pharmaceuticals Inc | Polimorfos de sepiapterina e sais dos mesmos |
| EP3548487A4 (en) | 2016-11-29 | 2020-04-29 | Censa Pharmaceuticals Inc. | POLYMORPHE SHAPE OF SEPIAPTERIN |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| CN112703002A (zh) | 2018-05-30 | 2021-04-23 | Ptc医疗Mp公司 | 增加墨蝶呤血浆暴露的方法 |
| US20210161901A1 (en) | 2018-05-30 | 2021-06-03 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| AU2019277372A1 (en) | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| WO2021026247A1 (en) | 2019-08-05 | 2021-02-11 | Ptc Therapeutics Mp, Inc. | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| JP2022549834A (ja) | 2019-09-25 | 2022-11-29 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 高フェニルアラニン血症の治療方法 |
-
2017
- 2017-11-28 BR BR112019010222A patent/BR112019010222A8/pt unknown
- 2017-11-28 US US16/464,771 patent/US11072614B2/en active Active
- 2017-11-28 IL IL301470A patent/IL301470A/en unknown
- 2017-11-28 KR KR1020237025450A patent/KR20230117467A/ko not_active Application Discontinuation
- 2017-11-28 CA CA3043502A patent/CA3043502A1/en active Pending
- 2017-11-28 CN CN201780084821.XA patent/CN110248948B/zh active Active
- 2017-11-28 JP JP2019548534A patent/JP7148533B2/ja active Active
- 2017-11-28 BR BR122021026889A patent/BR122021026889A8/pt unknown
- 2017-11-28 AU AU2017366879A patent/AU2017366879C1/en active Active
- 2017-11-28 MA MA046973A patent/MA46973A/fr unknown
- 2017-11-28 MX MX2019006206A patent/MX2019006206A/es unknown
- 2017-11-28 EP EP17876202.7A patent/EP3548497A4/en active Pending
- 2017-11-28 CN CN202310843616.4A patent/CN116903624A/zh active Pending
- 2017-11-28 KR KR1020197015403A patent/KR102561697B1/ko active IP Right Grant
- 2017-11-28 WO PCT/US2017/063517 patent/WO2018102315A1/en active Application Filing
- 2017-11-28 IL IL266955A patent/IL266955B2/en unknown
-
2019
- 2019-05-28 MX MX2021011676A patent/MX2021011676A/es unknown
- 2019-05-28 MX MX2021011683A patent/MX2021011683A/es unknown
- 2019-06-10 CO CONC2019/0006018A patent/CO2019006018A2/es unknown
-
2021
- 2021-06-09 US US17/342,910 patent/US11773097B2/en active Active
-
2022
- 2022-05-23 AU AU2022203481A patent/AU2022203481B2/en active Active
- 2022-09-22 JP JP2022151886A patent/JP2023002532A/ja active Pending
-
2023
- 2023-08-21 US US18/236,095 patent/US20240043426A1/en active Pending
-
2024
- 2024-01-18 AU AU2024200344A patent/AU2024200344A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011676A (es) | Polimorfos de sepiapterina y sales de los mismos. | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX2021002220A (es) | Forma cristalina de base libre de lorlatinib. | |
| MX2017008520A (es) | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| MY190243A (en) | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2020002271A (es) | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX2018003554A (es) | Benzamidas sustituidas con isoxazolina y analogos como insecticidas. | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| TW201613864A (en) | Novel compounds | |
| PH12020500105A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| PH12018500151A1 (en) | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof | |
| TW201613953A (en) | Process for the preparation of cyclic depsipeptides | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| JOP20190163A1 (ar) | منشط nrf2 | |
| PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
| MX2018015269A (es) | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| MX2022011476A (es) | Nuevas formas polimorficas de base de minociclina y procedimientos para su preparacion. |